By morning Leila was in a Board warehouse, not a hospital. The change of setting changed the problem. Instead of beds and pulse rates, she faced pallets, lot numbers, invoices and a shipping map stretched across a long table.
Zawadi Rono had arrived first. “We have about an hour before hospitals start screaming about stock,” she said. “If we freeze everything out of fear, we'll create a second emergency.”
Distributor manager Kibe stood opposite them. “Every Calm-X shipment remained inside cold chain. There is no basis to hold all supply.”
“We're not holding all supply,” Zawadi said. “We're isolating lots touching the formulation change.”
Leila built a timeline around the approval date. Lots released well before the change went into one group. Transition lots went into another. Current lots formed a third. CX-41N fell into the transition window alongside CX-40Q and CX-42B.
The shipping map filled with destinations—Kioo, East Ridge, Southline and several night pharmacies.
“We have one confirmed adverse event linked to one batch,” Zawadi reminded them. “We have a date discrepancy. We do not yet have a population signal.”
“Then there should be no recall,” Kibe said.
“There may be a targeted recall,” Zawadi replied. “The size of the action follows the evidence, not your inconvenience.”
Leila opened the formulation-change memo. The phrase enhanced retention appeared twice.
“Retention of what?” she asked.
“Therapeutic retention. Stability,” Kibe said.
“Does the memo say that?”
“The technical team can explain.”
It did not say chemical stability. It did not say patient retention either. Zawadi made Leila highlight the wording and request the underlying rationale rather than supplying her own meaning.
The continuity problem emerged quickly. Three hospitals held only newer stock. A broad shutdown would strand patients already dependent on a stabilizer. Verified old-formula stock remained at a Nocturne depot.
Kibe seized on that. “This is why central control exists.”
“Then use your old stock to support continuity after a targeted hold,” Leila said.
“On what basis?” Zawadi asked sharply.
Leila corrected herself. “On the basis of continuity after the hold. Not because we've proved the new formula caused the event.”
For the next two hours they separated lots by release date, formulation status and shipping chain. Cold-chain records were checked. In the end only three lots were placed under Board hold.
Before Leila signed the technical note, Zawadi required her disclosure about Nuru. Leila stated only that a close relative had a potentially related exposure through the distributor chain and that the relative's sample and consent would be independently managed.
Kibe shook his head. “You're putting the city at risk because of one case and a family story.”
“That's why we didn't shut down the city,” Leila said. “We held three lots.”
A call came from Southline asking whether a different batch in similar packaging could still be used. Leila checked its release date, cold-chain log and adverse-event history. It sat outside the three lots.
“We have no basis to add it to this hold,” she said.
Kibe looked surprised.
Zawadi issued the clarification. “Scope expands only when evidence expands.”
The formal order went out. CX-40Q, CX-41N and CX-42B were placed under targeted recall pending review. Nocturne was required to release verified old-formula stock to shortage sites.
Before leaving, Leila reread the formulation memo. It mentioned enhanced retention, a longer adherence window and packaging changes.
One expected thing was missing from the center of a drug-change memo.
Before the warehouse session ended, Southline called again about a batch outside the hold. Leila checked its release certificate, temperature record and incident history in front of Kibe. It had been released after approval and was not connected to any current adverse report. She refused to add it to the recall simply because the packaging looked similar.
That decision mattered. Her fear for Nuru could not become an invisible threshold for regulatory action. Zawadi documented the clarification and reminded every hospital that the order named three lots, not a whole product line. Nocturne, in turn, had to release verified older stock where the targeted hold created shortages.
There was no clinical reason stated for changing the formulation.